A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial

Recruiting

99 years or below

All

Phase 3

10 participants needed

1 Location

Brief description of study

This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA). There is a paucity of data on long-term use of the combination of ADT and an antipsychotic drug.The trial will assess long-term benefit of continuation of adjunctive therapy in subjects who achieve a level of clinical stabilization.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Major depressive disorder, depression
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 831294

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

Brief description of study

Eligibility of study

Find a site